These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38618204)

  • 1. Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial.
    Mulatero P; Wuerzner G; Groessl M; Sconfienza E; Damianaki A; Forestiero V; Vogt B; Brunner H; Gerlock T; Steele R; Schumacher C
    EClinicalMedicine; 2024 May; 71():102576. PubMed ID: 38618204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers.
    Mulatero P; Groessl M; Vogt B; Schumacher C; Steele RE; Brooks A; Hossack S; Brunner HR
    Br J Clin Pharmacol; 2023 Aug; 89(8):2483-2496. PubMed ID: 36914591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.
    Laffin LJ; Rodman D; Luther JM; Vaidya A; Weir MR; Rajicic N; Slingsby BT; Nissen SE;
    JAMA; 2023 Sep; 330(12):1140-1150. PubMed ID: 37690061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study.
    Tehlirian C; Peeva E; Kieras E; Scaramozza M; Roberts ES; Singh RSP; Pradhan V; Banerjee A; Garcet S; Xi L; Gale JD; Vincent MS; Krueger J
    Lancet Rheumatol; 2021 Mar; 3(3):e204-e213. PubMed ID: 38279383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.
    Dauvilliers Y; Arnulf I; Foldvary-Schaefer N; Morse AM; Šonka K; Thorpy MJ; Mignot E; Chandler P; Parvataneni R; Black J; Sterkel A; Chen D; Skobieranda F; Bogan RK
    Lancet Neurol; 2022 Jan; 21(1):53-65. PubMed ID: 34942138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and clinical characterization of CYP11B2 inhibition by dexfadrostat phosphate.
    Pignatti E; Kollar J; Hafele E; Schuster D; Steele RE; Vogt B; Schumacher C; Groessl M
    J Steroid Biochem Mol Biol; 2023 Dec; 235():106409. PubMed ID: 37827219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Di Lorenzo C; Khlevner J; Rodriguez-Araujo G; Xie W; Huh SY; Ando M; Hyams JS; Nurko S; Benninga MA; Simon M; Hewson ME; Saps M
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):238-250. PubMed ID: 38211604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
    Schlaich MP; Bellet M; Weber MA; Danaietash P; Bakris GL; Flack JM; Dreier RF; Sassi-Sayadi M; Haskell LP; Narkiewicz K; Wang JG;
    Lancet; 2022 Dec; 400(10367):1927-1937. PubMed ID: 36356632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
    Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
    Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
    Williams B; MacDonald TM; Morant SV; Webb DJ; Sever P; McInnes GT; Ford I; Cruickshank JK; Caulfield MJ; Padmanabhan S; Mackenzie IS; Salsbury J; Brown MJ;
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):464-475. PubMed ID: 29655877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
    Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial.
    Silverberg JI; Lio PA; Simpson EL; Li C; Brownell DR; Gryllos I; Ng-Cashin J; Krueger T; Swaidan VR; Bliss RL; Kim HD
    EClinicalMedicine; 2023 Jun; 60():102002. PubMed ID: 37396805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.